Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lisdexamfetamine
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lisdexamfetamine is a central nervous system stimulant and a prodrug of dextroamphetamine. It is primarily used to treat attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older, as well as moderate to severe binge eating disorder (BED) in adults[1][2][5]. After oral administration, lisdexamfetamine is converted by red blood cells into its active form, dextroamphetamine. Dextroamphetamine increases the availability of dopamine and norepinephrine in the brain by blocking their reuptake and promoting their release from presynaptic neurons[3][5]. Lisdexamfetamine was developed to provide a longer duration of action with reduced abuse potential compared to other amphetamines[5].
- Brand names
- VyvanseElvanse
- Other names
- lisdexamfetamine dimesylate
02
Targets
DAT (Dopamine plasma membrane transport protein)MAOA (Monoamine oxidase A)MAOB (Monoamine oxidase B)NET (Norepinephrine Transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on lisdexamfetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lisdexamfetamine.